Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BPTF | Q12830 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8340628 | 0.71 | — | — | |
| SCHEMBL30950521 | 0.70 | — | — | |
| SCHEMBL21224663 | 0.70 | — | — | |
| SCHEMBL3716286 | 0.70 | — | — | |
| SCHEMBL29766487 | 0.70 | — | — | |
| SCHEMBL1230750 | 0.70 | — | — | |
| SCHEMBL561730 | 0.69 | COMT (0.38) | COMTHTTKMT2AL3MBTL1RAB9A | |
| SCHEMBL14943589 | 0.68 | CYP1A2 (0.35) | COMTHTTKAT2BBRD9KMT2A | |
| SCHEMBL19723234 | 0.67 | KAT2B (0.36) | COMTHTTKAT2BBRD9KMT2A | |
| SCHEMBL782655 | 0.67 | ALDH1A1 (0.36) | COMTHTTKAT2BBRD9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | Mirati Therapeutics, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4043466-B1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4404932-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | Oric Pharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-112004816-B | PRC2 inhibitors | 米拉蒂医疗股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-11220509-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11091495-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210230168-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20210101904-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2021-04-08 | — | — | US | disclosed |
| US-20210032252-A1 | PRC2 Inhibitors | Mirati Therapeutics, Inc. | 2021-02-04 | — | — | US | disclosed |
| WO-2020247475-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3746446-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| CN-112004816-A | PRC2 inhibitors | 米拉蒂医疗股份有限公司 | 2020-11-27 | — | — | CN | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2019152419-A1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS, INC (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091495-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | COMT 2122/4885HTT 4531/4885KAT2B 157/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | COMT 1404/4885HTT 4500/4885KAT2B 181/4885 |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | BMI1, EZH2, SUZ12 | COMT 2622/4885HTT 4645/4885KAT2B 104/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | COMT 2323/4885HTT 4059/4885KAT2B 210/4885 |
| US-11220509-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | COMT 2089/4885HTT 4136/4885KAT2B 94/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | COMT 2622/4885HTT 4645/4885KAT2B 104/4885 |
| US-20210101904-A1 | PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | COMT 2369/4885HTT 2873/4885KAT2B 89/4885 |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | EZH2, BMI1, EZH1 | COMT 280/4885HTT 2843/4885KAT2B 92/4885 |
| US-20210032252-A1 | PRC2 Inhibitors | EZH2, BMI1, SUZ12 | COMT 2369/4885HTT 2873/4885KAT2B 89/4885 |
| US-20210230168-A1 | PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | COMT 2369/4885HTT 2873/4885KAT2B 89/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | COMT 2578/4885HTT 3908/4885KAT2B 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.